CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Applied Therapeutics Inc - APLT CFD

0.3865
11.76%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0504
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023624 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023624%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001401 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001401%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.438
Open 0.39
1-Year Change -93.9%
Day's Range 0.3818 - 0.405
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 2, 2025 0.4380 0.0185 4.41% 0.4195 0.4393 0.4126
Apr 1, 2025 0.4418 -0.0305 -6.46% 0.4723 0.4739 0.4380
Mar 31, 2025 0.4648 0.0198 4.45% 0.4450 0.4926 0.4450
Mar 28, 2025 0.4922 -0.0278 -5.35% 0.5200 0.5266 0.4884
Mar 27, 2025 0.5208 0.0108 2.12% 0.5100 0.5317 0.5066
Mar 26, 2025 0.5011 -0.0179 -3.45% 0.5190 0.5301 0.5011
Mar 25, 2025 0.5262 -0.0098 -1.83% 0.5360 0.5360 0.5067
Mar 24, 2025 0.5345 -0.0066 -1.22% 0.5411 0.5574 0.5202
Mar 21, 2025 0.5300 0.0602 12.81% 0.4698 0.5841 0.4612
Mar 20, 2025 0.4780 -0.0021 -0.44% 0.4801 0.4900 0.4671
Mar 19, 2025 0.4764 -0.0136 -2.78% 0.4900 0.5002 0.4763
Mar 18, 2025 0.4974 -0.0325 -6.13% 0.5299 0.5299 0.4788
Mar 17, 2025 0.5190 0.0309 6.33% 0.4881 0.5240 0.4793
Mar 14, 2025 0.4863 0.0063 1.31% 0.4800 0.5284 0.4749
Mar 13, 2025 0.4731 -0.0173 -3.53% 0.4904 0.5040 0.4683
Mar 12, 2025 0.4928 -0.0212 -4.12% 0.5140 0.5701 0.4686
Mar 11, 2025 0.5112 0.0249 5.12% 0.4863 0.5242 0.4850
Mar 10, 2025 0.4848 -0.0322 -6.23% 0.5170 0.5208 0.4769
Mar 7, 2025 0.5400 0.0725 15.51% 0.4675 0.5719 0.4675
Mar 6, 2025 0.4771 0.0191 4.17% 0.4580 0.4813 0.4418

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Applied Therapeutics, Inc. Company profile

About Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Applied Therapeutics Inc revenues was not reported. Net loss increased 12% to $105.6M. Higher net loss reflects General and administrative - Balancing increase of 66% to $15.7M (expense), Stock-based Compensation in SGA increase of 55% to $8.4M (expense), Other general & administrative expenses increase of 73% to $5.4M (expense).

Industry: Bio Therapeutic Drugs

545 5Th Avenue, Suite 1400
NEW YORK
NEW YORK 10017
US

People also watch

BTC/USD

81,382.95 Price
-4.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

US100

18,592.40 Price
-1.450% 1D Chg, %
Long position overnight fee -0.0236%
Short position overnight fee 0.0014%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,755.85 Price
-6.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

Gold

3,133.98 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0162%
Short position overnight fee 0.0080%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading